LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | GSK1059615 | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4527 | 4513 | 1.0031 | 1.0043 |
MDA-MB-231 | GSK1059615 | 0.12 | uM | LJP6 | 72 | hr | 1235 | 4126 | 4513 | 0.9141 | 0.8817 |
MDA-MB-231 | GSK1904529A | 0.12 | uM | LJP6 | 72 | hr | 1235 | 3949 | 4513 | 0.8750 | 0.8278 |
MDA-MB-231 | Omipalisib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 1518 | 4513 | 0.3365 | 0.0863 |
MDA-MB-231 | GSK 690693 | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4227 | 4513 | 0.9366 | 0.9128 |
MDA-MB-231 | GW843682X | 0.12 | uM | LJP6 | 72 | hr | 1235 | 3093 | 4513 | 0.6853 | 0.5666 |
MDA-MB-231 | HG-5-113-01 | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4463 | 4513 | 0.9889 | 0.9848 |
MDA-MB-231 | HG-5-88-01 | 0.12 | uM | LJP6 | 72 | hr | 1235 | 4271 | 4513 | 0.9463 | 0.9261 |
MDA-MB-231 | Imatinib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 4326 | 4513 | 0.9584 | 0.9428 |
MDA-MB-231 | JNK-9L | 0.12 | uM | LJP6 | 72 | hr | 1235 | 3525 | 4513 | 0.7811 | 0.6986 |
MDA-MB-231 | JW-7-24-1 | 0.12 | uM | LJP6 | 72 | hr | 1235 | 4098 | 4513 | 0.9080 | 0.8733 |
MDA-MB-231 | Lapatinib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 4135 | 4513 | 0.9162 | 0.8846 |
MDA-MB-231 | LDN-193189 | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4154 | 4513 | 0.9205 | 0.8905 |
MDA-MB-231 | Linifanib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 4721 | 4513 | 1.0460 | 1.0634 |
MDA-MB-231 | Linsitinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 3882 | 4513 | 0.8601 | 0.8074 |
MDA-MB-231 | Mitoxantrone | 0.12 | uM | LJP5 | 72 | hr | 1235 | 959 | 4513 | 0.2125 | -0.0845 |
MDA-MB-231 | Mitoxantrone | 0.12 | uM | LJP6 | 72 | hr | 1235 | 916 | 4513 | 0.2030 | -0.0975 |
MDA-MB-231 | MK2206 | 0.12 | uM | LJP6 | 72 | hr | 1235 | 3998 | 4513 | 0.8858 | 0.8428 |
MDA-MB-231 | Neratinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4531 | 4513 | 1.0040 | 1.0055 |
MDA-MB-231 | Nilotinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4416 | 4513 | 0.9784 | 0.9703 |
MDA-MB-231 | Nintedanib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 4658 | 4513 | 1.0321 | 1.0442 |
MDA-MB-231 | NU7441 | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4631 | 4513 | 1.0261 | 1.0359 |
MDA-MB-231 | Dactolisib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 1470 | 4513 | 0.3258 | 0.0715 |
MDA-MB-231 | NVP-TAE684 | 0.12 | uM | LJP6 | 72 | hr | 1235 | 3542 | 4513 | 0.7847 | 0.7036 |
MDA-MB-231 | Palbociclib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 2570 | 4513 | 0.5695 | 0.4072 |